索拉非尼对肝癌患者血清中肿瘤相关miRNAs的影响(4)
| 第1页 |
参见附件。
[9] Gauthier A，Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma：An update [J]. Hepatol Res，2013，43(2)：147-154.
[10] Yao J W，Sun W，Chen J，et al. Advances in the study of structural modifications of multi-target anticancer drug sorafenib [J]. Yao Xue Xue Bao，2012，47(9)：1111-1119.
[11] Mao WF，Shao MH， Gao PT，et al. The important roles of RET，VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib [J]. Acta Pharmacol Sin，2012，33(10)：1311-1318.
[12] Ju J，Jiang J，Fesler A. miRNA：the new frontier in cancer medicine [J]. Future Med Chem，2013，5(9)：983-985.
[13] Mahn R，Heukamp LC，Rogenhofer S，et al. Circulating microRNAs(miRNA) in serum of patients with prostate cancer [J]. Urology，2011，77(5)：1265-1269.
[14] Chang J，Nicolas E，Marks D，et al. miR-122，a mammalian liver-specific microRNA，is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1 [J]. RNA Biol，2004，1(2)：106-113.
[15] Xu J，Zhu X，Wu L，et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway [J]. Liver Int，2012，32(5)：752-760.
[16] Bai S，Nasser MW，Wang B，et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib [J]. J Biol Chem，2009，284(46)：32015-32027.
[17] Fornari F，Gramantieri L，Giovannini C，et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells [J]. Cancer Res，2009，69(14)：5761-5767.
(收稿日期：2013-11-13 本文编辑：李继翔)
您现在查看是摘要介绍页，详见PDF附件。